Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Free Report) saw a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 644,000 shares, a growth of 5.1% from the January 15th total of 612,700 shares. Currently, 10.9% of the company’s shares are short sold. Based on an average daily trading volume, of 33,700 shares, the days-to-cover ratio is currently 19.1 days.
Greenwich LifeSciences Stock Up 1.0 %
NASDAQ:GLSI opened at $12.51 on Wednesday. Greenwich LifeSciences has a 1-year low of $10.52 and a 1-year high of $21.44. The firm’s 50-day moving average price is $12.56 and its 200-day moving average price is $13.43.
Insider Activity at Greenwich LifeSciences
In other news, CEO Snehal Patel acquired 3,200 shares of the business’s stock in a transaction on Monday, December 30th. The shares were acquired at an average cost of $11.12 per share, with a total value of $35,584.00. Following the transaction, the chief executive officer now owns 5,539,302 shares in the company, valued at $61,597,038.24. The trade was a 0.06 % increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have purchased 10,500 shares of company stock worth $128,459 over the last 90 days. 51.67% of the stock is owned by company insiders.
Institutional Investors Weigh In On Greenwich LifeSciences
Analysts Set New Price Targets
Separately, HC Wainwright restated a “buy” rating and set a $38.00 price target on shares of Greenwich LifeSciences in a research report on Tuesday, February 11th.
Read Our Latest Research Report on GLSI
Greenwich LifeSciences Company Profile
Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
Featured Articles
- Five stocks we like better than Greenwich LifeSciences
- 3 Stocks to Consider Buying in October
- Hims & Hers Earnings Could Be a Game Changer—What to Do Now
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- Airline Stocks – Top Airline Stocks to Buy Now
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.